XDEMVY Sales Soar 150% as Tarsus Pharma Targets $2 Billion Peak Revenue Milestone

Tarsus Pharmaceuticals, Inc. (TARS) has achieved a dramatic turnaround in its financial performance for fiscal year 2025, driven by exceptional market reception of XDEMVY, its groundbreaking treatment for Demodex blepharitis—an eye condition caused by infestation of Demodex mites, microscopic parasites that, like grain mites and other ectoparasites, can proliferate on human skin and eyelids. This milestone marks a fundamental shift in how ophthalmologists approach eyelid disease management.

Strong Rx Uptake Drives Revenue Explosion in FY25

For the fourth quarter of 2025, the company reported a significant improvement in its operating losses, with net losses narrowing to $8.37 million ($0.20 per share) compared to $23.11 million ($0.60 per share) in the same period last year. More impressively, net product sales surged to $151.67 million from just $66.41 million a year earlier—a 128% quarter-over-quarter increase driven by approximately 130,000 XDEMVY units delivered to patients in the three-month period, substantially exceeding the prior year’s 58,500 units.

Full-year 2025 results underscore the product’s remarkable market penetration. Annual net losses plummeted to $66.42 million ($1.59 per share), down from $115.55 million ($3.07 per share) in 2024. Most notably, annual net product sales tripled to $451.36 million from $180.10 million—a striking 150% surge that reflects XDEMVY’s rapid adoption across U.S. ophthalmology practices.

“XDEMVY has driven a fundamental shift in eye care. In just two years, we have built broad access, changed how physicians treat, and established a durable and growing franchise, giving us confidence in a clear potential path to peak sales exceeding $2 billion,” stated Bobak Azamian, M.D., PhD, Chief Executive Officer and Chairman of Tarsus.

FDA-Approved Demodex Blepharitis Treatment Gains Market Traction

As the first and only FDA-approved therapy specifically designed to target Demodex blepharitis, XDEMVY addresses an untapped market segment within ophthalmology. The condition, caused by microscopic mite infestation, affects a substantial patient population that previously lacked targeted treatment options. XDEMVY’s rapid revenue growth demonstrates strong physician and patient acceptance, validating the significant unmet medical need.

The company’s cash position at year-end 2025 stood at $417.3 million in cash, cash equivalents, and marketable securities, providing a robust financial foundation for continued growth and development initiatives.

Ambitious Global Expansion Strategy Underway

Tarsus has set its sights on international markets, with XDEMVY positioned for transformative global reach. In Europe, the company expects regulatory approval of a preservative-free formulation in 2027, representing a strategic product refinement for overseas markets. In the Greater China region, partner Grand Pharmaceutical Group Ltd. anticipates potential approval in 2026, opening a significant market opportunity in one of the world’s largest pharmaceutical markets.

These timelines position XDEMVY for substantial revenue contributions from international markets within the next 12-24 months, complementing the company’s established U.S. commercial success.

Promising Pipeline Advances Beyond XDEMVY

Beyond its flagship product, Tarsus is advancing a robust pipeline of investigational therapies. TP-04, a sterile aqueous gel formulation of lotilaner, is currently under phase 2 clinical evaluation for potential treatment of ocular rosacea, with topline data anticipated in the first half of 2027. This indication addresses another significant ophthalmological unmet need.

Additionally, the company is developing TP-05, an oral tablet formulation of lotilaner, targeting Lyme disease prophylaxis and community malaria reduction. Phase 2 initiation for Lyme disease prevention is expected in the second quarter of 2026, representing Tarsus’s expansion beyond traditional ophthalmology into broader infectious disease management.

Outlook: Building a Multi-Billion Dollar Franchise

With XDEMVY delivering exceptional commercial traction and a focused pipeline of complementary assets, Tarsus has established clear pathways toward its $2 billion peak sales target. The combination of robust U.S. adoption, imminent global expansion, and advanced developmental programs positions the company at an inflection point. The stock’s performance—trading between $38.51 and $85.25 over the prior year and closing at $69.59—reflects market confidence in management’s execution and the company’s long-term value creation potential.